$AIP

RAZA SAIYED ATIQ sold $2.1M of AIP (indirect holdings)

RAZA SAIYED ATIQ sold 70,000 indirectly-held shares of Arteris, Inc. (AIP) at an average of $30.01 ($28.78–$30.30, $2.10M total) across 3 trades on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · RAZA SAIYED ATIQ
Published Aug 5, 2026, 10:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 10:08 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AIP
Neutral
medium confidence
Mentioned
$AIP
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AIPNeutralLow
01

Why it matters

The only new information is the size, timing, and structure of the director’s open-market sale under a 10b5-1 plan; it does not include guidance, litigation, or business updates.

02

Market read

Traders may note insider selling, but the 10b5-1 structure and lack of fundamental updates make this a low-signal catalyst.

03

What to watch

The filing does not disclose reasons for the sale, and the director ends with 0 shares, which can be misread without context of the plan’s start date and prior sales.

Relevance 5/10Novelty 3/10Timing: filed Aug 5, after-hours; transaction dated Aug 3

Background

The article is an SEC Form 4 insider transaction disclosure for Arteris, Inc. (AIP).

Company-level read

Ticker impact

$AIPNeutralMedium confidence
Context

Arteris director RAZA SAIYED ATIQ sold about $2.1M of AIP shares via an open-market sale under a 10b5-1 plan, leaving 0 shares.

Expected impact

Likely minimal price impact; any reaction would be sentiment-driven and short-lived unless accompanied by other company-specific news.

Evidence & confidence

Form 4 shows a pre-arranged 10b5-1 sale and the filing provides no new operational or financial information beyond the transaction details.

Market effects

No clear sector read-through from a single director 10b5-1 sale.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • Arteris, Inc.

    Company whose shares were sold by a director under a 10b5-1 plan.

  • RAZA SAIYED ATIQ

    Director who sold 70,000 shares of AIP for about $2.1M, indirect holdings, leaving 0 shares.

Related articles

MedAI 8/10

Arteris Inc. raises FY26 sales guidance to $95-98M range

Arteris Inc. raised its FY2026 revenue guidance to $95.0 million to $98.0 million, up from $91.0 million to $95.0 million previously. The new range is above the $94.578 million analyst consensus estimate, reflecting stronger-than-expected demand for its NoC interconnects and design automation tools, according to the company.

$AIPHighAI 9/10

Arteris, Inc. (AIP): Results of Operations and Financial Condition

Arteris, Inc. (AIP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991q2fy268-k.htm EX-99.1 Document Arteris Announces Financial Results for the Second Quarter and Estimated Third Quarter and Updated Full Year 2026 Guidance CAMPBELL, Calif. - August 6, 2026 - Arteris, Inc. (Nasdaq: AIP), a leading provider of semiconductor techn